The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical validation of a prognostic 7-marker IHC assay (7-IHC) in 382 patients (pts) with stage IB/IIA cutaneous melanoma (CM; MELARISK-001).
 
Teresa Amaral
Consulting or Advisory Role - CeCaVa; Delcath Systems; NeraCare GmbH; Novartis; Pierre Fabre
Research Funding - Agenus (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Biotech IOB (Inst); BMS GmbH & Co. KG (Inst); HUYA Bioscience International (Inst); Immunocore (Inst); MSD (Inst); NeraCare GmbH (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst); Skyline Diagnostics (Inst)
 
Stephan Forchhammer
Honoraria - Recordati
Research Funding - BioNTech SE (Inst); NeraCare GmbH (Inst); Skyline Diagnostics (Inst)
 
Eftychia Chatziioannou
No Relationships to Disclose
 
Iva Johansson
No Relationships to Disclose
 
Eduardo Nagore
No Relationships to Disclose
 
Esperanza Manrique-Silva
No Relationships to Disclose
 
Víctor Través-Zapata
No Relationships to Disclose
 
Barbara Van Leeuwen
No Relationships to Disclose
 
Marnix R. Jansen
No Relationships to Disclose
 
José Bañuls
No Relationships to Disclose
 
Noelia Jara
No Relationships to Disclose
 
María Niveiro de Jaime
No Relationships to Disclose
 
Ann-Sophie Bohne
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Mallinckrodt; Pierre Fabre; Sun Pharma
 
Jyri Teras
Stock and Other Ownership Interests - SYNLAB
 
Merrick I. Ross
Consulting or Advisory Role - Merck
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Merck
 
Alexander Christopher Jonathan van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); NeraCare GmbH; Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst); Skyline Diagnostics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; Evaxion Biotech; OncoC4; Turnstone Bio
Honoraria - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Turnstone Bio; Ultimovacs; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Roche; Sellas Life Sciences; Turnstone Bio; Turnstone Bio; Ultimovacs; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Moderna Therapeutics; Novartis; Roche
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Roger Olofsson Bagge
Stock and Other Ownership Interests - SATMEG Ventures
Consulting or Advisory Role - BD Bard; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Roche
Research Funding - BMS (Inst); Endomagnetics (Inst); NeraCare GmbH (Inst); Skyline Diagnostics (Inst)
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Immunocore; IO Biotech; Merck Serono; Merck Sharp & Dohme; Novartis; Philogen; Regeneron; Replimune; Roche; Sanofi/Aventis
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Regeneron; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche; Sanofi/Aventis